Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H15F2NO2 |
Molecular Weight | 375.3675 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(N=C2C=CC(F)=CC2=C1C(O)=O)C3=CC=C(C=C3)C4=C(F)C=CC=C4
InChI
InChIKey=PHEZJEYUWHETKO-UHFFFAOYSA-N
InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)
Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. Brequinar had been in phase II clinical trials by Bristol-Myers Squibb for the treatment of cancer and transplant rejection. However, this research has been discontinued.
Brequinar had been also in preclinical studys for the treatment of cytomegalovirus infections. However, this research has been discontinued.
Originator
Sources: http://en.pharmacodia.com/yaodu/html/v1/chemicals/27908be590d3ec381df976ecbf65df81.html
Curator's Comment: # Bristol-Myers Squibb
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
2600 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 1 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 1 Sources: Page: p.1406, 1407 |
DLT: Thrombocytopenia, Leucopenia... Disc. AE: Anemia... Other AEs: Stomatitis... Dose limiting toxicities: Thrombocytopenia (grade 4, 100%) AEs leading toLeucopenia (grade 2, 100%) discontinuation/dose reduction: Anemia (grade 1, 100%) Other AEs:Stomatitis (grade 3, 100%) Sources: Page: p.1406, 1407 |
210 mg/m2 1 times / day multiple, intravenous MTD Dose: 210 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 210 mg/m2, 1 times / day Sources: Page: p.986 |
unhealthy, ADULT n = 5 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 5 Sources: Page: p.986 |
DLT: Thrombocytopenia, Thrombocytopenia... Dose limiting toxicities: Thrombocytopenia (grade 4, 20%) Sources: Page: p.986Thrombocytopenia (grade 3, 40%) |
2300 mg/m2 1 times / week multiple, intravenous MTD Dose: 2300 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2300 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 3 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: Page: p.1406, 1407 |
DLT: Maculopapular rash, Skin eruption... Other AEs: Thrombocytopenia... Dose limiting toxicities: Maculopapular rash (grade 3, 33.3%) Other AEs:Skin eruption (grade 3, 33.3%) Mucositis (grade 3, 33.3%) Thrombocytopenia (grade 3, 66.7%) Sources: Page: p.1406, 1407 |
600 mg/m2 2 times / week multiple, intravenous MTD Dose: 600 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 600 mg/m2, 2 times / week Sources: Page: p.1407 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.1407 |
Other AEs: Anemia, Stomatitis... Other AEs: Anemia (grade 3, 25%) Sources: Page: p.1407Stomatitis (grade 3, 25%) Leucopenia (grade 2, 25%) Thrombocytopenia (grade 4, 50%) |
850 mg/m2 2 times / week multiple, intravenous MTD Dose: 850 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 850 mg/m2, 2 times / week Sources: Page: p.1407 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.1407 |
Other AEs: Thrombocytopenia, Stomatitis... Other AEs: Thrombocytopenia (grade 3, 25%) Sources: Page: p.1407Stomatitis (grade 3, 25%) |
350 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 350 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 350 mg/m2, 1 times / day Sources: Page: p.986 |
unhealthy, ADULT n = 1 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 1 Sources: Page: p.986 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anemia | grade 1, 100% Disc. AE |
2600 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 1 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 1 Sources: Page: p.1406, 1407 |
Leucopenia | grade 2, 100% DLT, Disc. AE |
2600 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 1 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 1 Sources: Page: p.1406, 1407 |
Stomatitis | grade 3, 100% | 2600 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 1 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 1 Sources: Page: p.1406, 1407 |
Thrombocytopenia | grade 4, 100% DLT, Disc. AE |
2600 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 2600 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2600 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 1 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 1 Sources: Page: p.1406, 1407 |
Thrombocytopenia | grade 3, 40% DLT |
210 mg/m2 1 times / day multiple, intravenous MTD Dose: 210 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 210 mg/m2, 1 times / day Sources: Page: p.986 |
unhealthy, ADULT n = 5 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 5 Sources: Page: p.986 |
Thrombocytopenia | grade 4, 20% DLT |
210 mg/m2 1 times / day multiple, intravenous MTD Dose: 210 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 210 mg/m2, 1 times / day Sources: Page: p.986 |
unhealthy, ADULT n = 5 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 5 Sources: Page: p.986 |
Maculopapular rash | grade 3, 33.3% DLT, Disc. AE |
2300 mg/m2 1 times / week multiple, intravenous MTD Dose: 2300 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2300 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 3 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: Page: p.1406, 1407 |
Mucositis | grade 3, 33.3% DLT, Disc. AE |
2300 mg/m2 1 times / week multiple, intravenous MTD Dose: 2300 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2300 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 3 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: Page: p.1406, 1407 |
Skin eruption | grade 3, 33.3% DLT, Disc. AE |
2300 mg/m2 1 times / week multiple, intravenous MTD Dose: 2300 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2300 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 3 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: Page: p.1406, 1407 |
Thrombocytopenia | grade 3, 66.7% | 2300 mg/m2 1 times / week multiple, intravenous MTD Dose: 2300 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2300 mg/m2, 1 times / week Sources: Page: p.1406, 1407 |
unhealthy, ADULT n = 3 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 3 Sources: Page: p.1406, 1407 |
Leucopenia | grade 2, 25% | 600 mg/m2 2 times / week multiple, intravenous MTD Dose: 600 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 600 mg/m2, 2 times / week Sources: Page: p.1407 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.1407 |
Anemia | grade 3, 25% | 600 mg/m2 2 times / week multiple, intravenous MTD Dose: 600 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 600 mg/m2, 2 times / week Sources: Page: p.1407 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.1407 |
Stomatitis | grade 3, 25% | 600 mg/m2 2 times / week multiple, intravenous MTD Dose: 600 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 600 mg/m2, 2 times / week Sources: Page: p.1407 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.1407 |
Thrombocytopenia | grade 4, 50% | 600 mg/m2 2 times / week multiple, intravenous MTD Dose: 600 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 600 mg/m2, 2 times / week Sources: Page: p.1407 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.1407 |
Stomatitis | grade 3, 25% | 850 mg/m2 2 times / week multiple, intravenous MTD Dose: 850 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 850 mg/m2, 2 times / week Sources: Page: p.1407 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.1407 |
Thrombocytopenia | grade 3, 25% | 850 mg/m2 2 times / week multiple, intravenous MTD Dose: 850 mg/m2, 2 times / week Route: intravenous Route: multiple Dose: 850 mg/m2, 2 times / week Sources: Page: p.1407 |
unhealthy, ADULT n = 4 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 4 Sources: Page: p.1407 |
PubMed
Title | Date | PubMed |
---|---|---|
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). | 1989 Aug 15 |
|
Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria. | 1998 Oct 15 |
|
Immunosuppressive drugs: the first 50 years and a glance forward. | 2000 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1450049
Advanced melanoma: Brequinar was given at a median weekly dose of 1200 mg/m2 intravenously.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9776318
10 uM of brequinar sodium completely inhibited the dihydroorotate-induced oxygen consumption of rat liver mitochondria.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1557
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
||
|
NCI_THESAURUS |
C2169
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL38434
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
100000088660
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
177387
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
C1560
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
m2646
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB05885MIG
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
DTXSID00242165
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
DB03523
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
96187-53-0
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
Brequinar
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
57030
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
C046943
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
5XL19F49H6
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY | |||
|
6204
Created by
admin on Sat Dec 16 16:52:20 GMT 2023 , Edited by admin on Sat Dec 16 16:52:20 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)